Patents by Inventor Philip Anthony Jennings
Philip Anthony Jennings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210347904Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: September 24, 2020Publication date: November 11, 2021Inventors: Lynn Dorothy POULTON, Adam CLARKE, Andrew James POW, Debra TAMVAKIS, George KOPSIDAS, Anthony Gerard DOYLE, Philip Anthony JENNINGS, Matthew POLLARD
-
Patent number: 10822422Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: GrantFiled: July 11, 2016Date of Patent: November 3, 2020Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20160333104Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: July 11, 2016Publication date: November 17, 2016Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20160264661Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: April 22, 2016Publication date: September 15, 2016Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Hoi Yi Wai, Andrew James Pow, George Kopsidas
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140086922Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: September 18, 2013Publication date: March 27, 2014Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Patent number: 8563697Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: GrantFiled: August 14, 2009Date of Patent: October 22, 2013Assignee: Cephalon Australia Pty. Ltd.Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Publication number: 20110319597Abstract: The present invention relates to domain antibodies which have modified framework regions such that the potency or level of binding of the domain antibody is improved. In particular the present invention relates to domain antibodies which bind TNFa in which changes have been made to framework sequences and to constructs including these domain antibodies.Type: ApplicationFiled: August 13, 2009Publication date: December 29, 2011Applicant: Caphalon Australia Pty. Ltd.Inventors: Raina Jui Yu Simpson, Zehra Elgundi, Anthony Gerard Doyle, Philip Anthony Jennings, Robert Daniel Gay, Adam William Clarke
-
Publication number: 20100040620Abstract: The present invention provides a binding complex comprising antibodies or antigen-binding fragments which bind to both Lewisy and Lewisb antigens, wherein the antibodies or antigen-binding fragments are in the form of multimers, and wherein the antibodies or antigen-binding fragments do not naturally form multimers.Type: ApplicationFiled: September 20, 2007Publication date: February 18, 2010Inventors: Linda Gillian Durrant, Philip Anthony Jennings
-
Publication number: 20040132121Abstract: The present invention relates to peptides having eubacterial b protein-binding properties and the surface of b protein with which said peptides and other proteins interact. The invention provides in vitro and in vivo assays for identifying compounds that modulate the interaction between b protein and proteins that interact therewith, and a method of controlling eubacterial infestation by modulating this interaction. The disclosed peptides can be used as templates for the design or selection of compounds that modulate the foregoing interaction.Type: ApplicationFiled: November 10, 2003Publication date: July 8, 2004Inventors: Brian Paul Dalrymple, Kritaya Kongsuwan, Gene-Louise Wilfiels, Philip Anthony Jennings, Gregory William Komp
-
Patent number: 6365730Abstract: The invention describes catalytic nucleic acid based compounds capable of cleaving nucleic acid polymers both in vivo and in vitro. Two embodiments of this invention are compounds with a short stem that does not base pair, a minizyme, and compounds with DNA hybridizing arms and RNA catalytic domain and stem, DNA-armed ribozymes. The compounds of this invention, while nucleotide based may be substituted or modified in the sugar, phosphate, or base. Methods of use and methods of treatment are also described.Type: GrantFiled: December 8, 1992Date of Patent: April 2, 2002Assignee: Gene Shears Pty. LimitedInventors: Philip Anthony Jennings, Maxine June McCall, Philip Hendry
-
Patent number: 6127114Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a plant, animal or viral target RNA, a region of defined sequence and a base paired stem region.Type: GrantFiled: May 17, 1995Date of Patent: October 3, 2000Assignee: Gene Shears Pty. Ltd.Inventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron
-
Patent number: 6083744Abstract: The invention describes catalytic nucleic acid based compounds capable of cleaving nucleic acid polymers both in vivo and in vitro. Two embodiments of this invention are compounds with a short stem that does not base pair, a minizyme, and compounds with DNA hybridizing arms and RNA catalytic domain and stem, DNA-armed ribozymes. The compounds of this invention, while nucleotide based may be substituted or modified in the sugar, phosphate, or base. Methods of use and methods of treatment are also described.Type: GrantFiled: June 7, 1995Date of Patent: July 4, 2000Assignee: Gene Shears Pty LimitedInventors: Philip Anthony Jennings, Maxine June McCall, Philip Hendry
-
Patent number: 6008343Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridisation to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.Type: GrantFiled: June 6, 1995Date of Patent: December 28, 1999Assignee: Gene Shears Pty. Ltd.Inventors: Philip Anthony Jennings, Maxine June Mc Call, Philip Hendry
-
Patent number: 6001989Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridisation to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.Type: GrantFiled: March 28, 1994Date of Patent: December 14, 1999Assignee: Gene Shears Pty LimitedInventors: Philip Anthony Jennings, Maxine June Mc Call, Philip Hendry
-
Patent number: 5972701Abstract: This invention provides catalytic molecules capable of cleaving target nucleotide sequences. More specifically, the invention provides an endonuclease having nucleotide sequences which are of sufficient length to allow hybridization to a target nucleotide sequence desired to be cleaved. The endonuclease contains a catalytic region comprising ribonucleotides and/or deoxyribonucleotides, or derivatives thereof which act to cleave a phosphodiester bond of the substrate nucleotide sequence. The catalytic region comprises nucleotides or derivatives thereof which are linked by linking groups which may comprise ribonucleotides, deoxyribonucleotides or combinations thereof.The endonucleases of the invention are useful in the cleavage of target RNAs associated with disease in humans and animals and in the inactivation of RNA transcripts in eukaryotic and prokaryotic cells, as well as the cleavage of RNA transcripts in-vitro.Type: GrantFiled: March 28, 1994Date of Patent: October 26, 1999Assignee: Gene Shears Pty LimitedInventors: Philip Anthony Jennings, Maxine June Mc Call, Philip Hendry
-
Patent number: 5906922Abstract: The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having formula (1), in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or is absent, R.sub.4 is H ir CH.sub.2 O--R.sub.3 ; and R.sub.1, R.sub.2 and R.sub.3 are the same or different and are either hydrogen, methyl, ethyl, hydroxyl or an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated, with the proviso that at least one of R.sub.1, R.sub.2 and R.sub.3 is an acyl group derived from a fatty acid, or to a compound having the formula (2): w . . . xyNHCH.sub.2 CH.sub.2 OR.sub.5, in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or absent, R.sub.5 is an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated.Type: GrantFiled: April 16, 1997Date of Patent: May 25, 1999Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Robert George Whittaker, Fiona Helen Cameron, Veronika Bender, Minoo Moghaddam, Philip Anthony Jennings
-
Patent number: 5840874Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a plant, animal or viral target RNA, a region of defined sequence and a base paired stem region.Type: GrantFiled: May 17, 1995Date of Patent: November 24, 1998Assignee: Gene Shears Pty. LimitedInventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron
-
Patent number: 5766942Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise nucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a target RNA, a region of defined sequence and a base paired stem region.Type: GrantFiled: February 8, 1994Date of Patent: June 16, 1998Assignee: Gene Shears Pty. LimitedInventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron
-
Patent number: 5747335Abstract: Compounds having highly specific endoribonuclease activity are described. The compounds of this invention, also known as ribozymes, comprise ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with a plant, animal or viral target RNA, a region of defined sequence and a base paired stem region.Type: GrantFiled: February 8, 1994Date of Patent: May 5, 1998Assignee: Gene Shears Pty. LimitedInventors: James Phillip Haseloff, Wayne Lyle Gerlach, Philip Anthony Jennings, Fiona Helen Cameron